Cardiology

Adverse events not up with six months of DAPT

(HealthDay)—For patients receiving an everolimus-eluting stent implantation, six months of dual antiplatelet therapy (DAPT) does not increase composite events compared with 12 months of DAPT, according to a study published ...

Cardiology

Cilostazol doesn't prevent periprocedural MI in ACS

(HealthDay)—For patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), adjunctive loading dose of cilostazol is not associated with prevention of periprocedural myocardial infarction ...

Cardiology

Young women at greater risk for adverse outcomes following PCI

Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are more likely to experience one-year adverse cardiovascular events due to risk factors such as diabetes ...

Cardiology

PCSK9 monoclonal antibodies show promise in ACS

(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the ...

page 18 from 30